Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.

[1]  Vernon E Walker,et al.  Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. , 2003, Journal of acquired immune deficiency syndromes.

[2]  M. Gerschenson,et al.  Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence? , 2002, Mitochondrion.

[3]  M. Poirier,et al.  Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. , 2002 .

[4]  M. Poirier,et al.  Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Gerschenson,et al.  Oxidative DNA damage in fetal tissues after transplacental exposure to 3'-azido-3'-deoxythymidine (AZT). , 2000, Carcinogenesis.

[6]  M. Poirier,et al.  Relationships between DNA incorporation, mutant frequency, and loss of heterozygosity at the TK locus in human lymphoblastoid cells exposed to 3'-azido-3'-deoxythymidine. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  T. Patterson,et al.  Incorporation of 3'-azido-3'-deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. , 1999, Journal of acquired immune deficiency syndromes.

[8]  L. Anderson,et al.  Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice. , 1999, Toxicology and applied pharmacology.

[9]  J. O’Neill,et al.  Genotoxicity of 3'-azido-3'-deoxythymidine in the human lymphoblastoid cell line, TK6: relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT. , 1999, Mutation research.

[10]  R. Tarone,et al.  Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. , 1999, AIDS.

[11]  R. Stark,et al.  Implications of the kinetics of zidovudine in the pregnant baboon following oral administration. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[12]  D. Valenti,et al.  Mitochondria as cell targets of AZT (zidovudine). , 1998, General pharmacology.

[13]  L. Anderson,et al.  Skin tumorigenesis and Ki‐ras and Ha‐ras mutations in tumors from adult mice exposed in utero to 3′‐azido‐2′,3′‐dideoxythymidine , 1998, Molecular carcinogenesis.

[14]  J. Gambertoglio,et al.  Intracellular Phosphorylation of Zidovudine (ZDV) and Other Nucleoside Reverse Transcriptase Inhibitors (RTI) Used for Human Immunodeficiency Virus (HIV) Infection , 1998, Pharmaceutical Research.

[15]  L. Mofenson.  ANTIRETROVIRAL THERAPY AND INTERRUPTION OF HIV PERINATAL TRANSMISSION , 1998 .

[16]  J. Unadkat,et al.  In vivo maternal-fetal-amniotic fluid pharmacokinetics of zidovudine in the pigtailed macaque: comparison of steady-state and single-dose regimens. , 1998, The Journal of pharmacology and experimental therapeutics.

[17]  L. Anderson,et al.  Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. , 1997, Journal of the National Cancer Institute.

[18]  D. Reynolds,et al.  A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. , 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[19]  T. Patterson,et al.  Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late-term rhesus macaques after maternal infusion. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[20]  S. Cox,et al.  Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea , 1997, Antimicrobial agents and chemotherapy.

[21]  L. Kalish,et al.  After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. , 1996, The Journal of infectious diseases.

[22]  J L Sullivan,et al.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1996, The New England journal of medicine.

[23]  D. Clive,et al.  Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. , 1996, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[24]  A. Adimora,et al.  Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties , 1996, JAMA.

[25]  D. Gomez,et al.  Preferential incorporation of 3'-azido-2',3'-dideoxythymidine (azt) in telomeric sequences of cho cells. , 1995, International journal of oncology.

[26]  D. Back,et al.  Metabolism of Zidovudine. , 1995, General pharmacology.

[27]  R. Newbold.  Cellular and molecular effects of developmental exposure to diethylstilbestrol: implications for other environmental estrogens. , 1995, Environmental health perspectives.

[28]  S. Devesa,et al.  Childhood cancer: overview of incidence trends and environmental carcinogens. , 1995, Environmental health perspectives.

[29]  M. Dalakas,et al.  Mitochondrial toxicity of antiviral drugs , 1995, Nature Medicine.

[30]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[31]  R. Albertini,et al.  Determination of hprt mutant frequencies in T-lymphocytes from a healthy pediatric population: statistical comparison between newborn, children and adult mutant frequencies, cloning efficiency and age. , 1994, Mutation research.

[32]  S G Grant,et al.  In vivo somatic mutation and segregation at the human glycophorin A (GPA) locus: phenotypic variation encompassing both gene-specific and chromosomal mechanisms. , 1993, Mutation research.

[33]  W. Parks,et al.  The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082) , 1993 .

[34]  M. Shelton,et al.  Comparative Pharmacokinetics of Antiviral Nucleoside Analogues , 1993, Clinical pharmacokinetics.

[35]  R. Sperling,et al.  Zidovudine Pharmacokinetics During Pregnancy , 1992, American journal of perinatology.

[36]  J. Pons,et al.  Placental passage of azathiothymidine (AZT) during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. , 1991, European journal of obstetrics, gynecology, and reproductive biology.

[37]  C. Lowery,et al.  Transplacental transfer of zidovudine in the near-term pregnant baboon. , 1990, American journal of obstetrics and gynecology.

[38]  D. Savitz,et al.  Parental occupation and childhood cancer: review of epidemiologic studies. , 1990, Environmental health perspectives.

[39]  S. Forenza,et al.  Induction of the SOS response in Escherichia coli by azidothymidine and dideoxynucleosides , 1990, Antimicrobial Agents and Chemotherapy.

[40]  J. A. Hill,et al.  Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U) , 1987, Antimicrobial Agents and Chemotherapy.

[41]  W. Bigbee,et al.  Measurements of the frequency of human erythrocytes with gene expression loss phenotypes at the glycophorin A locus , 1986, Human Genetics.

[42]  J K Haseman,et al.  Natural history of body weight gain, survival, and neoplasia in the F344 rat. , 1984, Journal of the National Cancer Institute.

[43]  R. Cleeland,et al.  Antibacterial activity of 2',3'-dideoxyadenosine in vivo and in vitro , 1981, Antimicrobial Agents and Chemotherapy.

[44]  A. Herbst,et al.  Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. , 1971, The New England journal of medicine.

[45]  F. Beland,et al.  Immunofluorescent localization and quantitation of 3'-azido-2',3'-dideoxythymidine (azt) incorporated into chromosomal DNA of human, hamster and mouse-cell lines. , 1994, International journal of oncology.

[46]  M. Poirier,et al.  Preferential incorporation of 3′‐azido‐2′,3′‐dideoxythymidine into telomeric DNA and Z‐DNA—containing regions of chinese hamster ovary cells , 1993, Molecular carcinogenesis.

[47]  R. Albertini,et al.  In vivo somatic mutations in humans: measurement and analysis. , 1990, Annual review of genetics.